AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
AbbVie
AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults
US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...
AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics
US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...
AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis
US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...
AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment
US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...
Zhaoke Ophthalmology Enrolls First Patient for Cyclosporine A Eye Gel Phase III Study
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the first patient enrollment in a Phase...
AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...
AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal
US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...
Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...
AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...
Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500
China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...
AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program
US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...